TICKERNERD
Menu
TRLVTRLVHealthcare · Drug Manufacturers - Specialty & Generic

TRLV Stock Forecast: Trulieve Cannabis Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$11
+8.29% on the day

The 7 Wall Street analysts covering Trulieve Cannabis Corp. hold a median 12-month price target of $19 — +71.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
88 / 100
Median analyst target
$19
Analysts covering
7
Total return, dividends reinvested
1W
+15.0%
1M
+23.9%
YTD
+27.7%
1Y
+40.3%
From 52W high
−14.6%
From 52W low
+133.2%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Trulieve Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Issuance
89
Quality
85
Value
80
Momentum
80
Revisions
50
Growth
38
Size
36
Volatility
33

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (33): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26TRLVHigh $21Median $19Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $15Median $19High $21

The green dot is the last close — the median target sits +71.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
20 July 2026Cantor FitzgeraldInitiatesOverweight$15
20 July 2026Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRLV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TRLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1756.4%
Analysts raising
3
Analysts cutting
0
Fundamentals

Trulieve Cannabis Corp. (TRLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.2×

Cheaper than 95% of US stocks

Price / sales
1.9×

Cheaper than 55% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
7.4×

Cheaper than 48% of US stocks

Growth & margins
Revenue growth (YoY)
−10.3%

Higher than 15% of US stocks

Earnings growth (YoY)
−10.3%

Higher than 26% of US stocks

Gross margin
59.9%

Higher than 73% of US stocks

Operating margin
12.8%

Higher than 69% of US stocks

Net margin
−41.6%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−47.7%

Higher than 22% of US stocks

Return on assets
3.3%

Higher than 67% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TRLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TRLVTrulieve Cannabis Corp.$2.1B
88
PRGOPerrigo Co. Plc$2.0B
69
BHCBausch Health Cos., Inc.$2.4B
96
BCRXBioCryst Pharmaceuticals, Inc.$2.4B
86
PBHPrestige Consumer Healthcare, Inc.$2.5B
59
ETONEton Pharmaceuticals, Inc.$1.8B
99
RGCRegencell Bioscience Holdings Ltd.$2.6B
4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Trulieve Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRLV news & analysis

Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE

PRNewsWire · 18 Aug 2026positive

Trulieve Cannabis Corp. announced it will ring the Closing Bell at the New York Stock Exchange at 4:00 P.M., marking it as the first U.S. cannabis company listed on the NYSE. The announcement was made by the company, a leading medical cannabis provider in the U.S.

Why it matters — This milestone highlights Trulieve's status as the first U.S. cannabis company listed on the NYSE, underscoring its prominent market position for investors following the company.

3 Marijuana Stocks For Investors To Consider

MarijuanaStocks · 12 Aug 2026neutral

The article discusses factors that drive marijuana stock trading, highlighting that US federal regulatory news has the biggest effect on the sector, and references recent legislation passed to reclassify cannabis to Schedule 3. It presents three marijuana stocks for investors to consider.

Why it matters — A TRLV watcher would care because the federal reclassification of cannabis to Schedule 3 is a regulatory event that could broadly affect the US marijuana sector, including Trulieve's operating environment.

Trulieve Completes Redomicile from British Columbia to Delaware

PRNewsWire · 11 Aug 2026neutral

Trulieve Cannabis Corp. announced the completion of its previously planned redomicile from British Columbia, Canada, to Delaware, United States. The move was announced on August 11, 2026, by the NYSE-listed medical cannabis company.

Why it matters — This corporate structural change relocates Trulieve's legal domicile to the U.S., which may affect its governance, regulatory treatment, and corporate structure for investors tracking the company.

Trulieve Cannabis: First NYSE-Listed Cannabis Stock Is A Buy

Seeking Alpha · 10 Aug 2026positive

Trulieve Cannabis became the first U.S. cannabis operator to uplist to the NYSE, gaining broader investor access and liquidity. The article also highlights a $50 million share repurchase program, a profitable Q1 2026 with $42 million in free cash flow, and the Schedule III reclassification of medical marijuana, which removes the 280E tax burden.

Why it matters — For TRLV watchers, the NYSE uplisting, share buyback, improved cash flow, and Schedule III tax relief represent notable developments that could expand investor access and strengthen the company's financial position.

Trulieve Cannabis Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Trulieve Cannabis reported second-quarter revenue of $271 million during its earnings call. The company outlined plans to expand in Georgia and Texas following recent changes in medical cannabis regulations and its June listing on the New York Stock Exchange.

Why it matters — A TRLV watcher would care because the reported revenue and expansion plans into Georgia and Texas signal the company's growth trajectory following regulatory changes and its NYSE listing.

FAQ

Frequently asked questions about TRLV stock

What is the TRLV stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Trulieve Cannabis Corp. have a median 12-month price target of $19, with estimates ranging from $15 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRLV stock a buy right now?

Of the 7 analysts covering Trulieve Cannabis Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trulieve Cannabis Corp. 88 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRLV?

As at 22 Aug 2026, Trulieve Cannabis Corp. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will TRLV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +71.2% from the last close, and Ticker Nerd's factor model ranks Trulieve Cannabis Corp. 88 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRLV stock forecast for 2030?

No analyst covering Trulieve Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $21 over the next 12 months.

How has TRLV stock performed over the past year?

Trulieve Cannabis Corp. returned +40.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Trulieve Cannabis Corp. do?

Trulieve Cannabis Corp. Common Stock represents ownership in Trulieve Cannabis Corp., a vertically integrated cannabis company focused on the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products in the United States.

What is the latest news on TRLV?

The most recent item we track (PRNewsWire, 18 Aug 2026): "Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE". Trulieve Cannabis Corp. announced it will ring the Closing Bell at the New York Stock Exchange at 4:00 P.M., marking it as the first U.S. cannabis company listed on the NYSE. The announcement was made by the company, a leading medical cannabis provider in the U.S.

Company

About Trulieve Cannabis Corp.

Trulieve Cannabis Corp. Common Stock represents ownership in Trulieve Cannabis Corp., a vertically integrated cannabis company focused on the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products in the United States. The company operates dispensaries and branded retail locations across several states, supported by in-house cultivation and processing facilities that help supply its product lineup. Its offerings include flower, edibles, vapes, concentrates, tinctures, topicals, and related accessories, sold under a portfolio of consumer brands. Trulieve also serves patients through home delivery in certain markets, making it an important participant in the regulated cannabis supply chain. Headquartered in Florida, Trulieve plays a significant role in both medical cannabis access and broader adult-use retail markets.

CEO Ms. Kimberly Rivers J.D. · 5,000 employees · United States · https://www.trulieve.com